1. Generics Bulletin
  2. >>Business
  3. >>Earnings

Mylan reforms plant as it ponders options

 
• By Aidan Fry

Mylan is overhauling its large-scale US manufacturing plant in Morgantown, West Virginia, and discontinuing several products in a bid to reduce complexity and improve its competitiveness. And with US market uptake of complex products such as generic Copaxone (glatiramer acetate) disappointing, the company has slashed the topend of its full-year turnover forecast by US$1.0 billion to US$12.25 billion as a board-level committee starts considering “all alternatives to unlock value” (Generics bulletin, 10 August 2018, page 1).

Mylan is overhauling its large-scale US manufacturing plant in Morgantown, West Virginia, and discontinuing several products in a bid to reduce complexity and improve its competitiveness. And with US market uptake of complex products such as generic Copaxone (glatiramer acetate) disappointing, the company has slashed the topend of its full-year turnover forecast by US$1.0 billion to US$12.25 billion as a board-level committee starts considering “all alternatives to unlock value” (Generics bulletin, 10 August 2018, page 1).

Having committed to “a robust improvement plan” in response to a 32-page ‘Form 483’ list of observations and deficiencies issued...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

Krka Passes €1bn Threshold In Just Six Months

 
• By Dean Rudge

Krka has reported its strongest-ever half-year results, surpassing €1bn in sales and growing EBITDA by 8%. Solid performance across most regions, particularly Eastern and Central Europe, supported stable margins and a positive full-year outlook.

Stelara Biosimilar Sees Stada’s Specialty Sales Start Strong In Q1

 
• By Dave Wallace

Stada’s Specialty division was boosted by the firm’s launch last year of a European Stelara biosimilar, even as generics growth remained muted in Q1.

Glenmark Adamant FDA Monroe Site Reinspection Could Happen ‘Any Time’

 
• By Dean Rudge

A weak second half in Glenmark’s India business during the firm’s 2025 financial year took the gloss off its earnings somewhat for the year. However, Glenmark is plotting several avenues to return to growth, in both of its core business regions: India and the US.

Loss Of Exclusivity Product Launches To Fuel Aurobindo’s FY26 Europe Growth

 
• By Vibha Ravi

Aurobindo is banking on launches of loss of exclusivity products and biosimilars to fuel sales in Europe as it awaits a US announcement on tariffs and predicts high single-digit growth overall during FY26 for now

More from Business

Krka Passes €1bn Threshold In Just Six Months

 
• By Dean Rudge

Krka has reported its strongest-ever half-year results, surpassing €1bn in sales and growing EBITDA by 8%. Solid performance across most regions, particularly Eastern and Central Europe, supported stable margins and a positive full-year outlook.

Kirsty Gives Biocon A First Interchangeable US Insulin Aspart Biosimilar

 
• By Dave Wallace

After years of waiting, Biocon Biologics has finally snagged US FDA approval for its insulin aspart biosimilar – along with a first designation of interchangeability. However, Sanofi’s Merilog version is already approved as a rival to Novo Nordisk’s Novolog.

Room For Improvement? EU Industry Prepares Feedback For SPC Manufacturing Waiver Review

 
• By Dave Wallace

As the European Commission prepares a formal evaluation of the SPC manufacturing waiver, the generics and biosimilars industry is getting ready to provide detailed feedback on what works – and what doesn’t. At Medicines for Europe’s legal affairs conference, delegates heard the latest updates.